Back to News
Market Impact: 0.3
HeartBeam Wins FDA Breakthrough Device Designation For At-Home Heart Attack Assessment; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationTechnology & Innovation
HeartBeam received FDA Breakthrough Device Designation for its HeartBeam System, which is being developed to help physicians assess potential heart attacks when symptoms begin, including at home. The designation is a positive regulatory milestone, but the article does not report FDA approval or commercialization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
BEAT0.80
More News
- HeartBeam stock soars on FDA breakthrough designation
- Dow Gains 100 Points; ISM Services PMI Falls In September
- Samsung, SK Hynix shares drop as Q3 earnings loom
- DeepSeek set to raise at least $12 bln in Tencent, CATL-led round- Bloomberg
- Security researcher claims to they found KVM guest-host escape flaw
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Choosing an AI Copilot for Equity Research
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience